SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 3.6% Stake in Vertex Pharmaceuticals
Beneficial Ownership Report
FMR LLC and its CEO, Abigail P. Johnson, have filed an amended Schedule 13G, reporting a beneficial ownership of 3.6% of Vertex Pharmaceuticals Inc.'s common stock as of December 31, 2024.
Summary
- FMR LLC and Abigail P. Johnson, its Chairman and CEO, jointly filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Vertex Pharmaceuticals Inc.
- As of December 31, 2024, FMR LLC and Abigail P. Johnson beneficially own an aggregate of 9,220,826.78 shares of Vertex Pharmaceuticals Inc. common stock.
- This aggregate amount represents 3.6% of the total outstanding common stock of Vertex Pharmaceuticals Inc.
- FMR LLC holds sole voting power over 8,484,281.69 shares and sole dispositive power over 9,220,826.78 shares.
- Abigail P. Johnson holds sole dispositive power over 9,220,826.78 shares, reflecting her deemed beneficial ownership through FMR LLC.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing (Schedule 13G) disclosing beneficial ownership. It is factual and does not contain information that would typically evoke strong positive or negative sentiment regarding the company's performance or outlook. The ownership percentage is significant but not indicative of a control-seeking stake.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of institutional ownership, indicating FMR LLC's continued investment in Vertex Pharmaceuticals. It does not provide specific insights into broader industry trends or competitive positioning beyond confirming a significant, but non-controlling, stake by a major asset manager in the pharmaceutical sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, confirming FMR LLC's continued investment in Vertex Pharmaceuticals. This is a routine disclosure and does not suggest any immediate impact on share price or corporate strategy.
Key Dates
| Date | Description |
|---|---|
| 2024-12-31 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-02-11 | Date of filing of the Schedule 13G Amendment No. 2. |
Keywords
Vertex Pharmaceuticals, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Ownership, Pharmaceuticals, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.